SARATOGA, Calif., Feb. 5, 2011 /PRNewswire/ — VisionCare
Ophthalmic Technologies, Inc., a developer of advanced visual
prosthetic devices for the treatment of end-stage age-related
macular degeneration, today announced Elka Nir of Giza Venture
Capital has joined VisionCare’s Board of Directors. Ms. Nir expands
the company’s Board to seven.
Ms. Nir heads the life sciences sector for Giza and serves on
the board of directors of five medical device companies in Israel
and the US. Prior to Giza, she led large multi-disciplinary teams
(R&D, supply chain, quality & regulatory, marketing) at a
division of Johnson & Johnson managing multi-million dollar
budgets and delivering innovative market leading products,
resulting in over $400 million in yearly revenues and double-digit
annual growth.
Ms. Nir holds a B.Sc. in Computer Science, from Technion-Israel
Institute of Technology, Haifa, Israel, a B.S. from the University
of Haifa, and completed the Senior Executive Education program at
Stanford University School of Business.
Allen W. Hill, VisionCare’s President and CEO, commented,
“VisionCare welcomes Elka to our Board. She was instrumental in
helping VisionCare raise $31.4 million in the recent Series E
financing. Elka’s extensive experience in executive roles and
raising funds for the development of new state of the art
solutions, via business collaboration with global market leaders,
will be of great assistance to VisionCare.”
On joining the VisionCare Board, Elka Nir commented, “VisionCare
has made tremendous progress in developing, clinically testing, and
obtaining FDA approval for its implantable telescope prosthesis in
patients with advanced forms of macular degeneration, which
disables hundreds of thousands of individuals in major markets.
VisionCare’s products show significant promise of improving vision
and quality of life for these individuals who now have no other
surgical option. I am looking forward to working with
‘/>”/>
